Alexion Pharmaceuticals reports that the European Commission has approved ULTOMIRIS® (ravulizumab) — for certain adults and children with atypical hemolytic uremic syndrome (aHUS) … more
Separately, Alexion reported topline results from a Phase 3 study of weekly self-administered subcutaneous ULTOMIRIS® in adults with paroxysmal nocturnal hemoglobinuria. The ongoing study met its primary objective … more